2.53
+0.04(+1.61%)
Currency In USD
| Previous Close | 2.49 |
| Open | 2.44 |
| Day High | 2.65 |
| Day Low | 2.42 |
| 52-Week High | 10.66 |
| 52-Week Low | 1.72 |
| Volume | 54,206 |
| Average Volume | 949,886 |
| Market Cap | 6.42M |
| PE | -0.36 |
| EPS | -6.94 |
| Moving Average 50 Days | 2.38 |
| Moving Average 200 Days | 2.58 |
| Change | 0.04 |
If you invested $1000 in GT Biopharma, Inc. (GTBP) since IPO date, it would be worth $2.99 as of March 13, 2025 at a share price of $2.53. Whereas If you bought $1000 worth of GT Biopharma, Inc. (GTBP) shares 5 years ago, it would be worth $27.56 as of March 13, 2025 at a share price of $2.53.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
GT Biopharma to Participate in the 10th Anniversary of the Innate Killer Summit
GlobeNewswire Inc.
Mar 04, 2025 12:00 PM GMT
SAN FRANCISCO, CALIFORNIA, March 04, 2025 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary TriKE® natura
GT Biopharma Announces Exercise of Warrants
GlobeNewswire Inc.
Feb 25, 2025 7:00 PM GMT
SAN FRANCISCO, CALIFORNIA, Feb. 25, 2025 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary TriKE® natural
GT Biopharma Announces Request for Withdrawal of Form S-1 Registration Statement
GlobeNewswire Inc.
Feb 25, 2025 12:00 PM GMT
SAN FRANCISCO, CALIFORNIA, Feb. 25, 2025 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary TriKE® natural